Black Diamond Therapeutics (BDTX) Change in Acquisitions & Divestments (2020 - 2026)

Black Diamond Therapeutics' Change in Acquisitions & Divestments history runs 7 years deep, the most recent figure standing at $19.5 million for Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 39.06% year-over-year to $19.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $106.6 million (down 20.0% YoY) and the FY2025 annual result came in at $119.1 million, down 14.78% from the prior year.
• Change in Acquisitions & Divestments was $19.5 million for Q1 2026 at Black Diamond Therapeutics, down from $33.0 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $40.5 million in Q2 2024 and bottomed at $8.2 million in Q3 2023.
• A 5-year average of $27.7 million and a median of $30.0 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments slumped 72.91% — and 2024, when it soared 263.64%.
• Black Diamond Therapeutics' Change in Acquisitions & Divestments stood at $26.0 million in 2022, then gained by 7.83% to $28.0 million in 2023, then rose by 9.68% to $30.8 million in 2024, then grew by 7.35% to $33.0 million in 2025, then plunged by 40.93% to $19.5 million in 2026.
• Business Quant data shows BDTX's Change in Acquisitions & Divestments at $19.5 million in Q1 2026, $33.0 million in Q4 2025, and $23.5 million in Q3 2025.